

Primary Care Providers' Beliefs and Recommendations and Use of Screening Mammography by their Patients

Jennifer S. Haas MD, MSc;^{1,2,7} William E. Barlow, PhD;⁶ Marilyn M. Schapira MD, MPH;⁸ Charles D. MacLean MD; Carrie N. Klabunde PhD;⁵ Brian L. Sprague PhD;³ Elisabeth F. Beaber PhD, MPH;⁶ Jane S. Chen;¹ Asaf Bitton MD;^{1,2} Tracy Onega PhD, MA, MS;⁴ Kimberly Harris MM,¹ Anna N. A. Tosteson, ScD⁴ on behalf of the PROSPR (Population-based Research Optimizing Screening through Personalized Regimens) consortium

From: ¹ Brigham and Women's Hospital, Boston, MA; ² Harvard Medical School, Boston, MA; ³ University of Vermont, Burlington, VT; ⁴ Geisel School of Medicine at Dartmouth and Norris Cotton Cancer Center; ⁵ Office of Disease Prevention, Office of the Director, National Institutes of Health, Bethesda, MD; ⁶ Fred Hutchinson Cancer Research Center, Seattle, WA; ⁷ Harvard T.H. Chan School of Public Health, Boston, MA; ⁸ University of Pennsylvania and the Philadelphia VA Medical Center, Philadelphia, PA.

Grant Support: This study was conducted as part of the National Cancer Institute-funded consortium, Population-Based Research Optimizing Screening through Personalized Regimens (PROSPR) (Grant numbers U54 CA163307, U54 CA163313, U54 CA163303, U01 CA163304).

Please address correspondence to:

Jennifer S. Haas, MD, MSc
Division of General Medicine and Primary Care
Brigham and Women's Hospital
1620 Tremont Street
Boston, MA 02120
Tel (617) 525-6652 / Fax (617) 732-7072
jhaas@partners.org

Word Count: 3,175

Tables: 3

Figures: 2

Number of References: 28

Running Title: Providers' Recommendations and Patients' Mammography Use

Key Words: mammography, variation in care, provider beliefs

Abstract

Background: Revised breast cancer screening guidelines have fueled debate about the effectiveness and frequency of *screening* mammography, encouraging discussion between women and their providers.

Objective: To examine whether primary care providers' (PCPs') beliefs about the effectiveness and frequency of *screening* mammography are associated with their patients' utilization.

Design: Cross-sectional survey data from PCP's (2014) from 3 primary care networks affiliated with the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium, linked with data about their patients' mammography use (2011-2014).

Participants : PCPs (n=209) and their female patients age 40-89 years without breast cancer (n=30,233).

Main Measures: Outcomes included whether: (1) women received a *screening* mammogram during a 2-year period; and (2) screened women had >1 mammogram during that period, reflecting annual screening. Principal independent variables were PCP beliefs about mammography's effectiveness and their recommendations for screening frequency.

Key Results: Overall 65.2% of women received ≥ 1 screening mammogram. *For women 40-48 years*, mammography use was modestly lower for those cared for by PCPs who believed that screening was ineffective compared with those who believed it was somewhat or very effective (59.1%, 62.3% and 64.7%; $p = 0.019$ after controlling for patient characteristics). Of women with PCPs who reported they did not recommend screening before age 50, 48.1% were nonetheless screened. *For women age 49-74 years*, the vast majority were cared for by providers who believed that screening was effective. Provider recommendations were not associated with screening frequency. *For women ≥ 75 years*, those cared for by providers who were uncertain about effectiveness had higher screening use (50.7%) than those cared for by providers who

believed it was somewhat effective (42.8%). Patients of providers who did not recommend screening were less likely to be screened than were those whose providers recommended annual screening, yet 37.1% of patients whose providers recommended against screening still received screening.

Conclusions: PCP beliefs about mammography's effectiveness and recommendations are only modestly associated with use, suggesting other likely influences on patient participation in mammography.

Word Count (abstract): 326

Introduction

Over the past decade there have been several well publicized revisions to national breast cancer screening guidelines.¹⁻⁴ These updates have re-invigorated both professional and lay debates about the effectiveness of screening mammography and how often women should be screened.⁵⁻⁷ For many women, these guidelines accentuate the importance of patient-provider discussion of individual screening harms and benefits.

Most studies of self-reported mammography use in the initial years following the 2009 US Preventive Services Task Force (USPSTF) recommendations have not demonstrated the less frequent use or later initiation of routine screening called for by the USPSTF,^{8,9} although a registry-based study documented a decline in use.¹⁰ Surveys of primary care providers (PCPs) have examined whether changes in guidelines have influenced provider beliefs about screening effectiveness and their recommendations for screening;^{11,12} the majority of PCPs report that they believe screening mammography is effective in reducing breast cancer mortality for women ages 40–74 years, and they have not implemented less frequent screening in part because of patient concerns.^{11,12}

Conceptual models hypothesize that variation in the use of cancer screening occurs at multiple health system levels, including organizations, practices, providers, and patients.^{13,14} While earlier studies suggest that provider demographic characteristics influence screening use (e.g., patients of female providers may receive more mammography^{15,16}), to our knowledge no U.S. studies have examined whether PCP beliefs about effectiveness of, and recommendations for, mammography screening are associated with actual use by their patients. A study from Denmark,

where invitations for mammography are managed centrally and PCPs are not directly involved in the breast cancer screening process, found that women in the panels of providers with a “positive” attitude about breast cancer screening were more likely to receive screening than those in a panel of a PCP with a more “negative” attitude.¹⁷ Understanding the multi-level influences on cancer screening use is critical for developing interventions designed to improve evidence-based screening. Further, as PCP recommendations are thought to be important to patient decisions, we sought to explicitly describe this relationship.

In this study, we linked survey data from PCPs to the utilization data of their patients to directly examine the association between provider beliefs about mammography’s effectiveness and recommendations for screening frequency on screening utilization.

Methods

Overview

This study was conducted as part of the NCI-funded Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium.¹⁸ The overall aim of PROSPR is to conduct multi-site, coordinated, trans-disciplinary research to evaluate and improve cancer screening processes. In 2014, we conducted a survey of PCPs affiliated with the three primary care networks of the PROSPR breast cancer research centers (response rate 57.6%) to ascertain provider beliefs about the effectiveness of mammography and their screening recommendations.

¹¹ Resident physicians were excluded. These data were linked to the participating PCPs’ patients’ screening utilization data between 2011-2014, obtained from PROSPR’s central data repository.

All sites received Institutional Review Board approval for active or passive consenting processes or a waiver of consent to enroll participants, link data, and perform analyses.

Settings and Study Population

Women 40-89 years of age without a known diagnosis of breast cancer or ductal carcinoma *in situ* and who had a primary care visit between 1/1/2011 and 9/30/2012 with a PCP affiliated with the clinical networks of: Brigham and Women's Faulkner Hospital (BWFH), Boston, MA; Dartmouth-Hitchcock Health System (DH), Lebanon, NH; and the University of Pennsylvania (PENN), Philadelphia, PA were eligible for inclusion. This timeframe was chosen to ensure that most women had two years of follow-up in the data repository. One of the provider networks (PENN) was limited to only 18-24 months of follow-up to observe screening mammograms after the PCP visit.

Data and Covariates

Provider-level data were obtained from the survey, which ascertained information about provider demographic and practice characteristics, including: age, gender, specialty (family or general practice, general internal medicine, gynecology, physician assistant, nurse practitioner, certified nurse midwives, other), medical school affiliation, number of out-patient office visits in a typical week, number of physicians at their practice, whether during the prior 12 months they had their clinical income adjusted based on their breast cancer screening performance, whether they had ever been sued for failure to diagnose cancer, and whether their primary practice had received NCQA-recognition as a medical home.

Also derived from the survey were the principal independent variables: provider beliefs concerning screening mammography effectiveness, and their recommendations for screening frequency. Survey questions about screening beliefs and recommendations were assessed by specific age groups (i.e., 40-49 years, 50-74 years, and ≥ 75 years), because guideline recommendations for screening vary by patient age. For each age group, PCPs were asked: (1) How effective do you believe screening mammography is for reducing cancer mortality for average-risk women? (Response options: very effective, somewhat effective, not effective, effectiveness not known, I am not sure); and (2) How often do you recommend screening mammography for most asymptomatic, average-risk women (in good health for their age)? (Response options: every year (12 months), every other year (24 months), I discuss interval options with patients, I do not routinely recommend).

Patient-level data were obtained from PROSPR's central data repository including: age (categorized as 40-48 years, 49-74 years and ≥ 75 years to reflect guideline differences by age; 49-year olds were included with the older group because they turned 50 years before the end of the two-year window), race/ ethnicity (white, black, Hispanic, Asian/ Pacific Islander, American Indian, mixed race/ other), type of health insurance (commercial, Medicare, Medicaid, uninsured/ medical assistance, other or missing), and Charlson comorbidity score (0, 1, 2+) ^{19,20}.

Survey data were linked to data from PROSPR's central repository using a unique provider identification code. Of the 73,266 women in the PROSPR data repository meeting the eligibility criteria for this study, 30,233 (41.2%) linked to a PCP who had completed a survey.

Outcome Variables

Outcome variables were obtained from PROSPR's central data repository and measured at the woman-level: (1) whether a woman received a screening mammogram during the 2 years following a PCP visit; and (2) for women who received a screening mammogram, whether they received >1 mammogram during that time period, reflecting the use of annual screening. A screening mammogram was defined as a mammogram coded by the radiology facility as being for screening; in addition, the woman did not have any prior imaging in the prior three months to avoid inclusion of diagnostic mammograms.

Statistical Analyses

We performed logistic regression analyses of the two binary outcomes. Potential predictors were assessed univariately and then multivariately, adjusting for other significant factors. For the assessment of patient characteristics we used a population-averaged generalized estimating equations (GEE) model to account for correlation among outcomes from the same PCP. To evaluate provider characteristics and beliefs we used GEE models adjusted for patient characteristics found to be significant in the patient-level GEE analyses. All models of provider characteristics and beliefs were adjusted for patient age, race/ ethnicity, and insurance status as well as calendar year and primary care network (BWFH, DH, PENN). Additionally, for evaluating the first outcome of "any screening use" we adjusted for comorbidity. Significant provider variables were tested in a larger joint multivariate model. The absolute measurement of screening may have been reduced at PENN due to shorter follow-up than the other two sites. However, we performed a sensitivity analysis excluding PENN (14% of the population) and there were no substantial differences. Thus, we report results for all three sites.

Results

Description of the Provider Population and the Patients Under Their Care

Twenty-three percent of providers were under the age of 40 years; these younger providers cared for 13.2% of the study cohort (Table 1). The majority of providers were female, general internists, and had a medical school affiliation. About one-third noted that their clinical income was adjusted based on their performance of breast cancer screening; few reported that they had been sued for failure to diagnose cancer. Slightly over half reported that they practiced in an NCQA-recognized medical home, and about 80% said they practiced in either a hospital-based or community-based office.

Provider Beliefs about Mammography Effectiveness and Patient Use

For women age 40-48 years, 30.6% of providers believed that mammography was not effective, 45.9% somewhat effective, 18.7% very effective, and 4.8% that effectiveness was not known or they were unsure about its effectiveness (Figure 1a). Use of mammography was modestly lower among women cared for by providers who believed that screening was not effective (59.1%) than among those whose providers thought it was somewhat effective (62.3%). Women cared for by providers who were uncertain about mammography's effectiveness had the highest use (74.2%). Differences in use by provider beliefs about effectiveness were significant ($p = 0.019$) after controlling for patient characteristics (Table 2). There was no overall association between provider beliefs about effectiveness and receipt of annual screening for this age group (Table 2), although those cared for by providers who thought that mammography was very effective

(43.9%) were more likely than those cared for by a provider who thought it was somewhat effective (39.2%) to receive mammography ($p = 0.026$).

For women age 49-74 years, more providers believed that mammography was very effective (50.2%), and few believed that mammography was not effective (2.4%) (Figure 1b). Women who were cared for by providers who were uncertain about mammography's effectiveness had the highest use of mammography (84.0%). Differences in use by provider beliefs about effectiveness were significant ($p < 0.0001$) after controlling for patient characteristics. In contrast to use of any screening, women cared for by providers who were uncertain of mammography's effectiveness were least likely to receive annual screening.

For women age 75 years and older, fewer providers believed that mammography was very effective compared with the younger groups; 30.6% indicated that mammography was not effective, and 23.8% were unsure about effectiveness (Figure 1c). Again, use of mammography was highest among patients cared for by providers who were uncertain about mammography's effectiveness (50.7%). Differences in use by provider beliefs about effectiveness were significant ($p=0.003$) after controlling for patient characteristics. There was no association between provider beliefs about effectiveness and receipt of annual screening for this age group.

PCP Recommendations for Mammography Frequency and Patient Use

For women age 40-48 years, 30.6% of providers recommended yearly screening, 6.2% recommended biennial screening, 55.0% discussed interval options with the patient, and 8.1% did not routinely recommend screening (Figure 2a). There was no association between providers'

recommended screening intervals and use of screening or use of annual screening (Table 2). Of note, mammography use among women cared for by providers who recommended yearly screening (64.4%) was similar to those cared for by providers who discussed interval options (63.6%); almost half of women cared for by providers who did not recommend screening in this age group received a mammogram.

For women age 49-74 years, more providers recommended yearly screening compared with the younger group, and fewer (14.0%) discussed interval options with women. No women were cared for by providers who did not routinely recommend screening for women in this age group (Figure 2b). Differences in use by provider recommendations for screening frequency were significant although modest in absolute difference ($p = 0.002$). There were no differences in provider recommendations for screening frequency and use of annual screening.

For women age 75 years and older, providers most commonly discussed interval options with their patients or did not recommend screening (Figure 2c). Mammography use was highest among women whose providers recommended yearly screening (52.9%) and lowest among women cared for by providers who did not routinely recommend screening in this age group. Nevertheless, 37.1% of women whose providers reported they did not routinely recommend screening for this age group received a mammogram. Differences in use by provider recommendations for screening frequency were significant ($p = 0.024$). There was no association between providers' recommended screening intervals and receipt of annual screening (Table 2).

Provider Characteristics and Screening Use

In models that adjusted for patient and provider characteristics (Table 2), patients of male providers were less likely than patients of female providers to receive a mammogram (odds ratio (OR) 0.63; 95% confidence interval (CI) 0.53 – 0.77) or annual screening (0.87; 0.78-0.97). Patients of family physicians were less likely than those of general internists, gynecologists, or mid-level providers to receive screening mammography or annual screening. Neither performance measurement for breast cancer screening nor history of being sued for failure to diagnose cancer were associated with screening use. There also was no association with provider-reported NCQA-recognized medical home status, but women of providers who practiced in a hospital-based office or a community health center were more likely than those whose providers practiced in a community-based office to receive mammography screening.

Use of Screening Mammography by Patient Characteristics

Overall 65.2% of women received at least one screening mammogram during the two-year study period (Table 3). Screening was higher among younger women than those 75 years and above. Hispanic women received screening mammograms at a higher rate than other racial/ ethnic groups. Women with commercial insurance received screening at a higher rate than uninsured women or those with public insurance. Screening use was lowest for women with a Charlson score of 2+. In the GEE model of patient factors associated with *any* screening use, age, race/ ethnicity, insurance, comorbidity and provider network were statistically significant. Among women who were screened, 49.0% received annual mammography. Patterns of annual screening were similar to any use of screening except that black women were less likely than white or Hispanic women to receive annual screening, women with Medicare were more likely to receive annual screening than were women with commercial insurance, and there was no association

with comorbidity. In the GEE model of patient factors associated with *annual* screening, the associations between age, race/ ethnicity, insurance, and provider network were statistically significant.

Discussion

Screening mammography's effectiveness and how often it should be used by women of different ages continues to fuel policy, clinical and public discourse.¹⁻⁷ While prior studies have examined physicians' beliefs about mammography's effectiveness,^{11,12} to our knowledge no U.S. studies have directly linked data on PCP beliefs and recommendations to actual utilization of their patients. We found that provider beliefs about mammography's effectiveness and recommendations for screening were only modestly associated with use. We found evidence of substantial use even among women of providers who do not routinely recommend mammography screening for certain age groups. For average risk women in their 40's, the USPSTF recommends that providers and patients engage in informed decision-making.³ Although the majority of providers in our study report that they practice informed decision-making with women in this age group, screening rates were similar to those observed among women whose providers recommended yearly screening. Importantly, almost half of women in their 40s who were seen by providers who reported that they did not routinely recommend screening still received mammography, and we observed a lack of association between provider recommendations for screening frequency and annual screening for women in all age groups. We also found that patients of providers who were unsure about the effectiveness or frequency of mammography were more likely to be screened, suggesting that patient preference may play a larger role in screening use when providers are uncertain. Importantly we did not find an

association between such practice characteristics as NCQA-recognition as a medical home or the use of provider incentives on the use of screening. These findings suggest that evidence-based implementation of mammography screening may require additional practice tools and policies beyond those currently available for shared decision making, like the broad dissemination of decision aids and perhaps centralized invitation and education for screening.

Our findings differ from those of a study of PCPs in solo practice in Denmark, where PCPs are not directly involved in ordering breast cancer screening because invitations to screening are managed centrally.¹⁷ Despite this more advisory role, this study suggested a positive relationship between a provider's more positive attitude about screening and the decision to initiate screening after the age of 50. Our findings may differ because the Danish study was focused on the decision to initiate screening whereas ours was focused on the use of screening and the frequency of screening, in addition to the important differences in how screening is implemented in the US and Denmark.

Understanding multi-level influences on the use of health care is critical to insuring the delivery of evidence-based care.^{13,14} Mammography screening is an exemplar of this complexity. Our findings suggest that there may be other important influences on personal screening decisions beyond discussion with PCPs or practice-level interventions to promote guideline-concordant screening. There are several potential reasons for these findings. PCPs may have limited time, skills or tools to engage in an individualized discussion of the harms and benefits of screening.^{21,22} Thus, screening may become a default option, especially with electronic health record (EHR) clinical decision support prompting clinicians to screen. This work supports the

need for better and more EHR-integrated tools for informed decision-making to help patients and providers discuss and consider the benefits and harms of screening, particularly for women in their 40s and those over the age of 75 where personal decision making may be most important.²³⁻

²⁶ Furthermore, there is a need for better EHR documentation of the occurrence of informed decision-making discussions. In addition to protocol reminders in EHRs for annual screening, recommendations and reminders to patients from radiology centers could also influence screening use.^{22,27} This underscores the importance of reconciling guideline recommendations for mammography across specialties and implementing systems for individualized screening reminders in EHRs. This work supports prior studies showing that provider demographic characteristics, particularly gender, may influence patients' use of cancer screening, but are not dominant factors,^{15,16} and that financial productivity incentives are not associated with mammography use.²⁸ Importantly, patient beliefs and behaviors may have broader influences than the recommendations of a PCP. Social networks and the media likely influence women's screening decisions.^{6,7}

Strengths of this study include use of multi-level data about patients, providers, and primary care practices. The study also has limitations. We did not survey patients about their screening beliefs or other influences on screening use, such as friends, family or the media. We did not assess details of PCPs shared decision-making practices. PCP survey data were not collected longitudinally and provider beliefs and practices may be evolving. Although we examined patients and their PCPs from three primary care networks, these findings may not be generalizable to other health care settings or other regions of the US beyond the northeast where the attitudes of women and PCPs may vary. Despite these limitations, our paper has strengths

beyond the diversity of practice networks. All patients saw their provider at least once, making it possible to discuss screening mammography. Because of our large sample, we were able to adjust for patient, provider and practice characteristics.

PCP beliefs about mammography's effectiveness and recommendations for screening frequency are only modestly associated with use. These results suggest that there are other important influences on women's decisions to participate in screening mammography. Further elucidation of these factors may inform the development of tools to support shared decision making that incorporate evidence about both the effectiveness and limitations of screening mammography as well as patient values and preferences.

Acknowledgements:

The authors thank the participating PROSPR Research Centers for the data they have provided for this study. A list of PROSPR investigators and contributing research staff is provided at:

<http://healthcaresdelivery.cancer.gov/prospr/>

This study was conducted as part of the National Cancer Institute-funded consortium, Population-Based Research Optimizing Screening through Personalized Regimens (PROSPR) (Grant numbers U54 CA163307, U54 CA163313, U54 CA163303, U01 CA163304).

The authors declare no conflicts of interest.

References

1. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2009;151(10):727-737, W237-742.
2. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009;151(10):716-726, W-236.
3. Siu AL, Force USPST. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med.* 2016.
4. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. *JAMA.* 2015;314(15):1599-1614.
5. Smith RA, Kerlikowske K, Miglioretti DL, Kalager M. Clinical decisions. Mammography screening for breast cancer. *N Engl J Med.* 2012;367(21):e31.
6. Rabin RC. For Women, a More Complicated Choice on Mammograms. *New York Times.* February 11, 2014, 2014.
7. How Often Do You Really Need a Mammogram? How much is too much? Many disagree, but with women's best interests at heart. 2015; <http://health.usnews.com/health-news/patient-advice/articles/2015/06/18/how-often-do-you-really-need-a-mammogram>. Accessed June 1, 2016.
8. Dehkordy SF, Hall KS, Roach AL, Rothman ED, Dalton VK, Carlos RC. Trends in Breast Cancer Screening: Impact of U.S. Preventive Services Task Force Recommendations. *Am J Prev Med.* 2015;49(3):419-422.

9. Pace LE, He Y, Keating NL. Trends in mammography screening rates after publication of the 2009 US Preventive Services Task Force recommendations. *Cancer*. 2013;119(14):2518-2523.
10. Sprague BL, Bolton KC, Mace JL, et al. Registry-based Study of Trends in Breast Cancer Screening Mammography before and after the 2009 U.S. Preventive Services Task Force Recommendations. *Radiology*. 2014;270(2):354-361.
11. Haas JS, Sprague BL, Klabunde CN, et al. Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines. *J Gen Intern Med*. 2016;31(1):52-59.
12. Corbelli J, Borrero S, Bonnema R, et al. Physician adherence to U.S. Preventive Services Task Force mammography guidelines. *Womens Health Issues*. 2014;24(3):e313-319.
13. Onega T, Beaber EF, Sprague BL, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. *Cancer*. 2014;120(19):2955-2964.
14. Zapka JG, Taplin SH, Solberg LI, Manos MM. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. *Cancer Epidemiol Biomarkers Prev*. 2003;12(1):4-13.
15. Lurie N, Slater J, McGovern P, Ekstrum J, Quam L, Margolis K. Preventive care for women. Does the sex of the physician matter? *N Engl J Med*. 1993;329(7):478-482.
16. Kreuter MW, Strecher VJ, Harris R, Kobrin SC, Skinner CS. Are patients of women physicians screened more aggressively? A prospective study of physician gender and screening. *J Gen Intern Med*. 1995;10(3):119-125.

17. Jensen LF, Mukai TO, Andersen B, Vedsted P. The association between general practitioners' attitudes towards breast cancer screening and women's screening participation. *BMC cancer*. 2012;12:254.
18. Beaber EF, Kim JJ, Schapira MM, et al. Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. *J Natl Cancer Inst*. 2015;107(6):djv120.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383.
20. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005;43(11):1130-1139.
21. Sabatino SA, McCarthy EP, Phillips RS, Burns RB. Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. *Cancer Detect Prev*. 2007;31(5):375-383.
22. Schapira MM, Sprague BL, Klabunde CN, et al. Inadequate Systems to Support Breast and Cervical Cancer Screening in Primary Care Practice. *J Gen Intern Med*. 2016.
23. Schonberg MA, Walter LC. Talking about stopping cancer screening-not so easy. *JAMA Intern Med*. 2013;173(7):532-533.
24. Schonberg MA, Hamel MB, Davis RB, et al. Development and evaluation of a decision aid on mammography screening for women 75 years and older. *JAMA Intern Med*. 2014;174(3):417-424.

25. Schonberg MA, Breslau ES, McCarthy EP. Targeting of mammography screening according to life expectancy in women aged 75 and older. *Journal of the American Geriatrics Society*. 2013;61(3):388-395.
26. Seitz HH, Gibson L, Skubisz C, et al. Effects of a risk-based online mammography intervention on accuracy of perceived risk and mammography intentions. *Patient Educ Couns*. 2016;in press.
27. ACR and SBI Continue to Recommend Regular Mammography Starting at Age 40. 2015; <http://www.acr.org/About-Us/Media-Center/Press-Releases/2015-Press-Releases/20151020-ACR-SBI-Recommend-Mammography-at-Age-40>. Accessed June 3, 2016.
28. Wee CC, Phillips RS, Burstin HR, et al. Influence of financial productivity incentives on the use of preventive care. *The American journal of medicine*. 2001;110(3):181-187.

Figure 1. Association between Provider Beliefs about Mammography Effectiveness and Use of Screening by their Patients, by Age.

Figure 1a. 40 – 48 years

Figure 1b. 49 – 74 years

Figure 1c. 75+ years

NOTES:

Figures show unadjusted rates and the adjusted p-values.

Figure 2. Association between Provider Recommendations for Frequency of Screening and Use of Screening by their Patients, by Age.

Figure 2a. 40 – 48 years

Figure 2b. 49 – 74 years

Figure 2c. 75+ years

NOTES:

Figures show unadjusted rates and the adjusted p-values.

Table 1. Description of PCPs and Patients under their Care.

	Provider N (%) N = 209	Patients N (%) N = 30,233
<u>Provider Characteristics</u>		
Age:		
< 40 years	47 (23.2%)	3,953 (13.2%)
40 – 49 years	73 (36.0%)	12,377 (41.3%)
50 – 59 years	43 (21.2%)	7,583 (25.3%)
60 + years	40 (19.7%)	6,087 (20.3%)
Female:	136 (65.1%)	23,972 (79.3%)
Provider specialty:		
Family medicine (MD/ DO)	39 (18.7%)	4,906 (16.2%)
General internal medicine (MD/ DO)	138 (66.1%)	22,108 (73.1%)
Gynecology (MD/ DO)	17 (8.1%)	1,430 (4.7%)
Physician Assistant, Nurse Practitioner, Certified Nurse Midwife	11 (5.3%)	811 (2.7%)
Other	4 (1.9%)	978 (3.2%)
Affiliated with a Medical School:	185 (90.2%)	28,081 (93.6%)
Typical week, # of office visits:		
<= 25	39 (19.2%)	3,720 (12.6%)
26 – 50	56 (27.6%)	8,942 (30.2%)
51 – 75	69 (34.0%)	11,868 (40.1%)
76+	39 (19.3%)	5,067 (17.1%)
During the past 12 months, clinical income was adjusted based on breast cancer screening:		
Yes	64 (31.5%)	8,357(28.3%)
No	124 (61.1%)	18,096 (61.3%)
Not sure	15 (7.4%)	3,081 (10.4%)
Ever sued for failure to diagnose cancer		
Yes	15 (7.3%)	2,066 (6.9%)
<u>Provider-Reported Practice Characteristics</u>		
Clinical provider network		

University of Pennsylvania	79 (37.8%)	4,198 (13.9%)
Dartmouth-Hitchcock Health System	47 (22.5%)	11,000 (36.9%)
Brigham and Women's Faulkner Hospital	83 (39.7%)	15,035 (49.7%)
National Committee for Quality Assurance (NCQA)-recognized medical home:		
Yes	113 (55.4%)	14,342 (48.1%)
Practice type:		
Hospital-based office	79 (38.9%)	12,541 (41.8%)
Community-based office (not health center)	89 (43.8%)	11,888 (39.6%)
Community health center	16 (7.9%)	3,140 (10.5%)
Other	19 (9.4%)	2,417 (8.1%)
Number of physicians in practice:		
<5	21 (10.3%)	3,990 (13.3%)
5-10	71 (34.8%)	8,343 (27.9%)
11-20	65 (31.9%)	10,550 (35.2%)
21+	47 (23.0%)	7,057 (23.6%)

NOTE:

Provider data were missing for: age (n = 6 providers), number of office visits/ week (6), performance reporting (12); sued for failure to diagnose cancer (8); practice in NCQA-recognized medical home (10), practice location (6), medical school affiliation (4), number of physicians in practice (10).

Table 2. Provider and Practice Characteristics Associated with Screening Use after Adjustment for Patient Factors.

	Received a Screening Mammogram			Among those with a Screening Mammogram, Received Annual Screening		
	OR	95% CI	P-value *	OR	95% CI	P-value *
<u>Provider Belief in Effectiveness of Screening Mammography</u>						
Women Age 40 – 48 years			0.019			0.177
Not effective	0.84	0.70 – 1.00	0.045	1.06	0.93 – 1.21	0.405
Somewhat effective	1.00	Referent		1.00	Referent	
Very effective	1.10	0.90 – 1.34	0.361	1.22	1.02 – 1.45	0.026
Effectiveness not known or Not sure	1.46	0.97 – 2.22	0.073	1.05	0.81 – 1.37	0.703
Women Age 49 – 74 years			<.0001			<.0001
Not effective	1.15	0.93 – 1.41	0.207	1.05	0.87 – 1.27	0.616
Somewhat effective	1.00	Referent		1.00	Referent	
Very effective	0.94	0.76 – 1.16	0.540	0.94	0.83 – 1.06	0.296
Effectiveness not known or Not sure	1.55	1.29 – 1.86	<.0001	0.72	0.63 – 0.84	<.0001
Women Age 75+ years			0.003			0.632
Not effective	0.81	0.54 – 1.20	0.284	0.92	0.62 – 1.35	0.659
Somewhat effective	1.00	Referent		1.00	Referent	
Very effective	0.63	0.38 – 1.03	0.065	0.66	0.35 -1.24	0.193
Effectiveness not known or Not sure	1.36	1.00 – 1.86	0.053	0.95	0.69 – 1.32	0.765
<u>Provider Recommendation for Screening Frequency</u>						
Women Age 40 – 48 years			0.164			0.157
Every year	1.00	Referent		1.00	Referent	
Every other year	0.74	0.52 – 1.05	0.092	0.87	0.52 – 1.46	0.600
Discuss interval options	0.92	0.78 – 1.09	0.325	0.88	0.77 - 1.00	0.050

Do not routinely recommend	0.66	0.41 – 1.05	0.078	1.00	0.80 – 1.26	0.970
Women Age 49 – 74 years			0.002			0.358
Every year	1.00	Referent		1.00	Referent	
Every other year	1.59	1.19 – 2.13	0.002	1.12	0.91 – 1.37	0.290
Discuss interval options	1.48	1.09 – 2.02	0.012	1.18	0.94 – 1.47	0.153
Women Age 75+ years			0.024			0.176
Every year	1.00	Referent		1.00	Referent	
Every other year	0.69	0.43 – 1.12	0.136	1.05	0.56 – 1.98	0.874
Discuss interval options	0.86	0.53 – 1.40	0.557	0.89	0.50 – 1.58	0.679
Do not routinely recommend	0.56	0.35 – 0.89	0.014	0.69	0.38 – 1.25	0.216
<u>Provider Characteristics</u>						
Provider gender			<0.0001			0.011
Male	0.63	0.53-0.77	<0.0001	0.87	0.78 – 0.97	0.011
Female	1.00	Referent		1.00	Referent	
Provider specialty:			<0.0001			0.011
Family medicine (MD/ DO)	0.57	0.44-0.72	<0.0001	0.83	0.71 – 0.96	0.012
General internal medicine (MD/ DO)	1.00	Referent		1.00	Referent	
Gynecology (MD/ DO)	0.97	0.73-1.28	0.823	1.32	1.00 – 1.73	0.049
Physician Assistant, Nurse Practitioner, Certified Nurse Midwife	1.13	0.76-1.67	0.544	0.88	0.67 – 1.17	0.388
Other	0.71	0.41-1.22	0.212	1.00	0.72 – 1.37	0.991
Affiliated with a Medical School			0.184			0.343
Yes	1.32	0.88-1.98	0.184	1.10	0.85 – 1.41	0.343
No	1.00	Referent		1.00	Referent	
During the past 12 months, clinical income was adjusted based on breast cancer screening			0.152			0.812

Yes	1.42	0.97-2.06	0.068	0.96	0.75 – 1.23	0.755
No	1.00	Referent		1.00	Referent	
Not sure	1.40	0.97-2.02	0.073	1.04	0.83 – 1.31	0.732
Ever sued for failure to diagnose cancer			0.919			0.602
Yes	1.01	0.86-1.18	0.919	1.04	0.89 – 1.22	0.602
No	1.00	Referent		1.00	Referent	
Provider-Reported Practice Characteristics						
National Committee for Quality Assurance (NCQA)-recognized medical home			0.398			0.117
Yes	0.93	0.77-1.11	0.398	0.88	0.75 – 1.03	0.117
No	1.00	Referent		1.00	Referent	
Practice type:			0.0008			0.028
Hospital-based office	1.40	1.16-1.68	0.0003	1.10	1.00 – 1.22	0.054
Community-based office (not health center)	1.00	Referent		1.00	Referent	
Community health center	1.57	1.22-2.02	0.0004	1.03	0.85 – 1.24	0.784
Other	1.39	1.11-1.74	0.0044	1.06	0.87 – 1.29	0.555

NOTES:

OR: odds ratio; 95% CI: 95% confidence interval

* First p-value for each characteristic is for the overall difference among the categories of that variable and is based on the score test from the GEE model. All subsequent p-values reflect the comparison of that particular value to the referent category and are based on the Wald test from the GEE model.

GEE models account for clustering of patients within primary care provider. Models adjust for all patient covariates (age, race/ ethnicity, insurance status, Charlson comorbidity score, calendar year, and clinical provider network) except where noted due to small numbers in some models; provider characteristics were then added individually to these models. Models of 2+ screens versus one screen did not include Charlson scores. Individuals with missing values for Charlson score or race were excluded. Those with missing insurance status were designated as a separate category and included unless the number of unknowns was too small to be modeled. For the models in women aged 75 or greater, insurance and race were not included due to small numbers.

Table 3. Patient Characteristics Associated with the Use of Screening Mammography and Receipt of Annual Screening

Characteristic	Had a Screening Mammogram					Among those with a Screening Mammogram, Received Annual Screening			
	Eligible (N)	Screened (N)	% Screened of Eligible	Adj. OR	95% CI	Annual Screen (N)	% Annual Screen of Screened	Adj. OR	95% CI
Overall	30,233	19,715	65.2%			9,659	49.0%		
Age									
40-48	11,045	6,888	62.4%	1.00	Referent	2,831	41.1%	1.00	Referent
49-74	17,229	11,971	69.5%	1.31	1.20-1.42	6,366	53.2%	1.39	1.29-1.50
75-87	1,959	856	43.7%	0.49	0.41-0.59	462	54.0%	1.26	1.05-1.50
Race/ethnicity									
Hispanic	2,298	1,780	77.5%	1.87	1.55-2.26	891	50.1%	1.01	0.88-1.17
White, non-Hispanic	22,196	14,194	64.0%	1.00	Referent	7,161	50.4%	1.00	Referent
Black, non-Hispanic	3,808	2,465	64.7%	1.23	1.08-1.40	1,014	41.4%	0.80	0.70-0.91
Asian	867	574	66.2%	1.05	0.88-1.24	267	46.5%	0.93	0.74-1.15
Native American/Alaskan Native	37	19	51.4%	0.56	0.31-1.02	12	63.3%	1.74	0.73-4.15
Mixed race/Other	249	137	55.0%	1.02	0.80-1.29	48	35.0%	0.89	0.64-1.24
Insurance									
Medicaid	1,204	690	57.3%	0.68	0.59-0.79	242	35.1%	0.68	0.57-0.81
Medicare	5,230	3,052	58.4%	0.82	0.77-0.89	1,697	55.6%	1.16	1.06-1.27
Commercial	21,160	14,383	68.0%	1.00	Referent	6,991	48.6%	1.00	Referent
Other	628	424	67.5%	1.00	0.83-1.21	215	50.7%	0.98	0.82-1.17
Uninsured/Medical Assistance	1,838	1,139	62.0%	0.56	0.48-0.64	513	45.0%	0.75	0.66-0.86
Unknown	173	27	15.6%	0.15	0.10-0.23	1	3.7%	0.08	0.01-0.56
Charlson comorbidity score									
0	22,736	15,033	66.1%	1.00	Referent	7,362	49.0%	Not included	
1	4,430	2,899	65.4%	0.92	0.86-1.00	1,431	49.4%		
2+	2,991	1,734	58.0%	0.66	0.59-0.75	862	49.7%		

Clinical provider network									
University of Pennsylvania	4,198	2,246	53.5%	1.00	Referent	744	33.1%	1.00	Referent
Dartmouth-Hitchcock Health System	11,000	6,485	59.0%	1.11	0.87-1.40	3,119	48.1%	1.08	0.88-1.31
Brigham and Women's Faulkner Hospital	15,035	10,984	73.1%	1.96	1.62-2.39	5,796	52.8%	1.47	1.21-1.78

NOTES:

OR: odds ratio; 95% CI: 95% confidence interval for the OR

Odds ratios adjust for all patient factors shown in the table. GEE models account for clustering of patients by primary care provider. Model of screening use adjusted for age, race/ ethnicity, insurance status, Charlson comorbidity score, calendar year and clinical provider network. Model of multiple screening use adjusted for same covariates except Charlson comorbidity score was not included.

Patient data were missing for: race/ ethnicity (n = 778 patients), and Charlson score (76).

Figure 1. Association between Provider Beliefs about Mammography Effectiveness and Use of Screening by their Patients, by Age.




Figure 2. Association between Provider Recommendations for Frequency of Screening and Use of Screening by their Patients, by Age.

